Tumor Biology

, Volume 34, Issue 6, pp 3879–3885

Downregulation of programmed cell death 4 (PDCD4) in tumorigenesis and progression of human digestive tract cancers

  • Gang Ma
  • Hao Zhang
  • Ming Dong
  • Xinyu Zheng
  • Iwata Ozaki
  • Sachiko Matsuhashi
  • Kejian Guo
Research Article

DOI: 10.1007/s13277-013-0975-9

Cite this article as:
Ma, G., Zhang, H., Dong, M. et al. Tumor Biol. (2013) 34: 3879. doi:10.1007/s13277-013-0975-9

Abstract

Nowadays, digestive tract cancers become the commonest neoplasia and one of the leading causes of cancer deaths worldwide. The development of diagnosis and therapy is urgently required. Programmed cell death 4 (PDCD4), a new tumor suppressor, has been documented to be a potential diagnostic tool and treatment target for neoplasia due to the inhabitation of tumor promotion/progression and metastasis. However, its role in human digestive tract cancers is few available up to now. In this study, we examined the expression of PDCD4 in human digestive tract cancers (61 gastric cancer, 65 colorectal cancer, and 69 pancreatic cancer patients) by Western blot analysis, reverse transcription (RT)-PCR, and immunohistochemistry. Western blot, RT-PCR, and immunohistochemistry examination showed that expressions of PDCD4 were significantly lower in cancers specimens than in noncancerous tissues. Among the different differentiated cancer tissues, PDCD4 expression was significantly lower in moderately or poorly differentiated cancers than in well-differentiated cancers (p < 0.05). Our findings suggested that PDCD4 might be a potentially valuable molecular target in diagnosis and therapy for human digestive tract cancers.

Keywords

PDCD4 Digestive tract cancers Western blot RT-PCR Immunohistochemistry 

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Gang Ma
    • 1
  • Hao Zhang
    • 1
  • Ming Dong
    • 1
  • Xinyu Zheng
    • 1
  • Iwata Ozaki
    • 2
  • Sachiko Matsuhashi
    • 3
  • Kejian Guo
    • 1
  1. 1.Department of Surgery, First Affiliated HospitalChina Medical UniversityShenyangPeople’s Republic of China
  2. 2.Division of Hepatology and Metabolism, Department of internal Medicine, Saga Medical SchoolSaga UniversitySagaJapan
  3. 3.Health Administration Center, Saga Medical SchoolSaga UniversitySagaJapan